Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Kristina Drizyte‐Miller

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7049-2934; OpenAlex author ID A5012787124. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 4 papers

Papers 8

  1. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Co-author DOI 10.1126/scisignal.adu7145↗
  2. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1757↗
  3. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Co-author DOI 10.1158/0008-5472.can-25-1507↗
  4. Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance Co-author DOI 10.64898/2025.12.01.691471↗
  5. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  6. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  7. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0391↗
  8. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kirsten L. Bryant · 6 shared papers, 2021–2025 · strength 0.99
  2. Adrienne D. Cox · 6 shared papers, 2021–2025 · strength 0.99
  3. Clint A. Stalnecker · 6 shared papers, 2021–2025 · strength 0.99
  4. Channing J. Der · 6 shared papers, 2021–2025 · strength 0.99
  5. Emanuel F. Petricoin · 4 shared papers, 2023–2025 · strength 0.69
  6. Mariaelena Pierobon · 4 shared papers, 2021–2025 · strength 0.59
  7. Jennifer E. Klomp · 3 shared papers, 2021–2025 · strength 0.41
  8. Andrew M. Waters · 3 shared papers, 2021–2025 · strength 0.41
  9. Lee M. Graves · 2 shared papers, 2025 · strength 0.39
  10. Ryan N. Robb · 2 shared papers, 2025 · strength 0.37
  11. Mallory K. Roach · 2 shared papers, 2025 · strength 0.37
  12. Emanuel F. Petricoin · 2 shared papers, 2021–2025 · strength 0.30
  13. Jonathan M. DeLiberty · 2 shared papers, 2021–2025 · strength 0.28
  14. J. Nathaniel Diehl · 2 shared papers, 2021–2025 · strength 0.28
  15. Bjoern Papke · 2 shared papers, 2021–2023 · strength 0.23
  16. Craig M. Goodwin · 2 shared papers, 2021–2023 · strength 0.23
  17. John P. Morris · 1 shared paper, 2025 · strength 0.19
  18. Sarah E. Ackermann · 1 shared paper, 2025 · strength 0.19
  19. Naim U. Rashid · 1 shared paper, 2025 · strength 0.18
  20. A. Cole Edwards · 1 shared paper, 2025 · strength 0.18
  21. Priya S. Hibshman · 1 shared paper, 2025 · strength 0.18
  22. Autumn J. McRee · 1 shared paper, 2023 · strength 0.13
  23. Ye S. Lee · 1 shared paper, 2021 · strength 0.09
  24. Calvin Jay Kuo · 1 shared paper, 2021 · strength 0.09
  25. Christopher M Counter · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.